Pharmaceuticals
2024ASCO｜Memorial Sloan Kettering Cancer Center (MSK)'s Prof. Wungki Park Unveils Precision Targeting of TF in Pancreatic Cancer, Signaling ADC Drug Innovations
Introduction: ADC Drug Breakthrough Targets TF in Pancreatic Cancer CHICAGO, June 12, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, held inChicago from May 31 to June 4, shone a spotlight on MRG004A, a novel antibody-drug conjugate (ADC) designed to tr...
2024-06-12 19:31
1954
Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions
SAN FRANCISCO and SUZHOU, China, June 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2024-06-12 08:00
3868
Last patient in: Laminar Pharmaceuticals S.A. completes recruitment for CLINGLIO, the phase 2b/3 Clinical Trial of idroxioleic acid (LAM561) in combination with RT and TMZ for adults with newly diagnosed glioblastoma
140 patients have been recruited at sites in Spain, Italy, France and United Kingdom. The open readout of the trial is expected by late 2024. Laminar aims to submit regulatory filings or conditional marketing authorization by early 2025. PALMA DE MALLORCA, Spain, June 12, 2024 /PRNewswire/ -- Lam...
2024-06-12 02:15
2427
Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)
OSAKA, Japan and WALTHAM, Mass., June 11, 2024 /PRNewswire/ -- Ono Pharmaceutical, Co., Ltd. (Chairman and CEO:Gyo Sagara, "Ono") today announced that it has successfully completed the tender offer, previously announced on April 30, 2024 to acquire all outstanding shares of common stock of a US b...
2024-06-11 20:30
2072
Chengdu's influence being felt across the world
CHENGDU, China, June 11, 2024 /PRNewswire/ -- Openness is a defining characteristic of contemporaryChina. In recent years, Chengdu, capital of Sichuan province, has used its location as a key hub in the Belt and Road Initiative and as a starting point of the ancient Southern Silk Road. By deepen...
2024-06-11 16:44
11367
111, Inc., Scrianen Announce Strategic Direct Supply Partnership to Expand Nationwide Reach and Improve Drug Accessibility
SHANGHAI, June 11, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, announced that the Company has ent...
2024-06-11 15:57
3983
Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient GIST Approved by the China CDE
SUZHOU, China, and ROCKVILLE, Md., June 11, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the Center for Drug Evaluation (CDE) ofChina'...
2024-06-11 11:25
4155
Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024
--Up to 68.2% mean relative reduction in liver fat content from baseline among biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients receiving 12-week treatment of ASC41 --Significant and clinically meaningful reductions in liver fat, alanine aminotransferase(ALT), as...
2024-06-11 08:10
2695
Element Six and Orbray partner to deliver the world's highest quality wafer-scale single crystal synthetic diamond
GRESHAM, Ore. and TOKYO, June 11, 2024 /PRNewswire/ -- Element Six
2024-06-11 08:00
4961
Octapharma's continuing dedication to improving the lives of people with rare bleeding disorders to be showcased at ISTH 2024
* Octapharma to present new clinical and scientific findings for wilate® and Nuwiq® at the upcoming ISTH 2024 Congress * New data and clinical study developments to be showcased in seven oral presentations, two posters and two Supported Symposia LACHEN, Switzerland, June 10, 2024 /PRNewswire/...
2024-06-10 21:09
3257
Kangpu Biopharmaceuticals to Present Results from Phase 2a of KPG-818 in SLE at EULAR 2024
HEFEI, China, June 10, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals today announced that a poster tour presentation highlighting the Phase 2a clinical data of KPG-818 in patients with Systemic Lupus Erythematosus (SLE) will be presented at the upcoming Annual European Congress of Rheumatology E...
2024-06-10 20:00
2603
FDA Grants Fast Track Designation to GCBP and Novel Pharma's GC1130A
* FDA's Fast Track designation speeds up the development of new biologic drugs for rare diseases YONGIN, South Korea, June 10, 2024 /PRNewswire/ -- GC Biopharma (006280. KS) and Novel Pharma have announced that the U.S. FDA has granted Fast Track Designation for their jointly developed MPSIIIA ...
2024-06-10 16:18
3114
J INTS BIO, ASCO 2024 - JIN-A02 showed tumor reductions including brain metastasis in the ongoing first-in-human, dose-finding Phase 1 clinical study
SEOUL, South Korea, June 10, 2024 /PRNewswire/ -- J INTS BIO provided an update of its ongoing Phase 1 clinical study of JIN-A02, a 4th generation EGFR-TKI for NSCLC treatment, during the 3rd of June poster session of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting held at Mc...
2024-06-10 13:56
2091
ILJIN SNT Co., Ltd. Announces Its Intention to Vote Against Aurinia Pharmaceuticals's Revised Equity Incentive Plan Proposal
SEOUL, South Korea, June 7, 2024 /PRNewswire/ -- Dear Fellow Shareholders, ILJIN SNT Co., Ltd. ("ILJIN") is a long-standing investor of Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company"), and, together with its affiliates, currently holds more than 5% of Aurinia's common stock. As one of...
2024-06-07 23:49
6144
IONETIX Produces First Batch of Actinium-225
LANSING, Mich., June 7, 2024 /PRNewswire/ -- IONETIX, a leading cyclotron technology innovator, isotope producer, and radiopharmaceutical manufacturer, announced today the successful production of Actinium-225 ("Ac-225") at its isotope manufacturing facility located inLansing, Michigan. This fir...
2024-06-07 20:27
2304
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024
New translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection BRII-179 as add-on therapy induces functional antibody responses and contributes toimproved sustained HBsAg loss in PEG-IFNa-t...
2024-06-07 19:00
3829
Clinical Data of First-in-class HBV-specificTCR T Cell Therapy (SCG101) Presented at ESAL Congress Showing Improved Overall Survival in HBV-related Hepatocellular Carcinoma
SINGAPORE, June 7, 2024 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, announced that clinical data from its first-in-class autologous hepatitis B virus (HBV)-specific...
2024-06-07 16:51
3413
MLB Announces IND Approval by US FDA to Initiate Phase 1 Trial of TML-6, a New Era Multi-Target Drug for the Treatment of Alzheimer's Disease
TAINAN, June 7, 2024 /PRNewswire/ -- MLB (Merry Life Biomedical Company, Ltd.,
Taiwan: https://www.tmlbio.com/
2024-06-07 15:00
2760
Qilu Pharmaceutical's Three Clinical Studies on Cancer Immunotherapy Presented at ASCO 2024
JINAN, China, June 6, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting convened fromMay 31 to June 4, 2024 in Chicago, USA, adopting a hybrid format. Among the presented works, three clinical studies from Qilu Pharmaceutical were selected for poster sessio...
2024-06-07 14:51
2296
MicuRx: Successful Completion of Phase I Clinical Trial for Self-Developed MRX-8 Antibacterial Drug in China
* According to the World Health Organization (WHO), millions of patients face treatment difficulties or even life-threatening conditions due to resistant bacterial infections each year. * MRX-8 not only shows excellent safety and tolerability but also demonstrates strong antibacterial activit...
2024-06-06 19:52
2473
Week's Top Stories
Most Reposted
HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 310 media titles]
2026-02-26 09:30
Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 308 media titles]
2026-02-26 19:57
SMU and Fudan Launch Region's First Tech-Focused DBA
[Picked up by 300 media titles]
2026-03-02 09:15Infobip is set to launch AgentOS to orchestrate autonomous AI-driven customer journeys at scale
[Picked up by 289 media titles]
2026-03-02 09:00
Klook's Spring Readiness Index shows how Asia's travelers are preparing for spring travel across Japan, South Korea, and Mainland China
[Picked up by 288 media titles]
2026-03-03 15:49
Most Read
COLUMBIA ASIA HOSPITAL BUKIT JALIL LAUNCHES NEW CATH LAB TO STRENGTHEN HEART CARE SERVICES
2026-03-02 14:24
8373
